Omega Fund Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Omega Fund Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-89,702	Closed	-$63.4K	–	12
2025 Q3	$63.4K	Sell	89,702 -231,800	-72%	-$176K	0.03%	12
2025 Q2	$273K	Hold	321,502	–	–	0.18%	13
2025 Q1	$193K	Hold	321,502	–	–	0.11%	13
2024 Q4	$271K	Hold	321,502	–	–	0.18%	11
2024 Q3	$675K	Hold	321,502	–	–	0.42%	10
2024 Q2	$383K	Sell	321,502 -39,401	-11%	-$126K	0.28%	11
2024 Q1	$1.88M	Sell	360,903 -114,174	-24%	-$348K	1.21%	9
2023 Q4	$404K	Buy	+475,077	New	+$365K	0.33%	13

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Omega Fund Management's ENGNW Position: Q4 2025 in Review

Omega Fund Management sold out of enGene Therapeutics Warrants (ENGNW) in Q4 2025, closing a stake of 89,702 shares — an estimated $63.4K sold.

Omega Fund Management first reported a position in ENGNW in Q4 2023 and held it in 8 quarters. The position peaked at $1.88M in Q1 2024. 14 funds tracked by Wall St. Rank hold ENGNW as of Q4 2025.

Omega Fund Management reported no remaining enGene Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
Omega Fund Management sold 89,702 enGene Therapeutics Warrants shares in Q4 2025, an estimated $63.4K.
Omega Fund Management first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 8 quarters.
Omega Fund Management's enGene Therapeutics Warrants position peaked at $1.88M in Q1 2024.
14 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q4 2025.

Based on Omega Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.